Unibioscreen And Drais Pharmaceuticals Partner To Develop And Commercialize Unbs5162 For Treatment Of Cancer Drais Pharmaceuticals, Inc. and Unibioscreen S.A. announced that they have entered into a global agreement to develop and commercialize UNBS5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer. UNBS5162 was discovered by Unibioscreen and is currently in Phase I trials in the United States in cancer patients with advanced solid tumors or lymphoma.
Source: www.medicalnewstoday.comGlobal Study Shows That Majority Of Women With Osteoporosis Do Not Consider Themselves At Higher Risk For Fractures Results from the Global Longitudinal study of Osteoporosis in Women (GLOW) showed that 55 percent of women diagnosed with osteoporosis do not believe they are at a higher risk of fractures than their peers. This latest study from GLOW included more than 60,000 women over age 55 and was presented at the American Society for Bone and Mineral Research (ASBMR) 30th Annual Meeting.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
